Preclinical trials have shown that P2RY12 inhibitors could reduce the tumor spread in melanoma, ovarian, breast, lung, and pancreatic cancers (24, 25, 47–51). The gene discussed is P2RY12; the disease is familial pancreatic carcinoma.